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Candida is a major human fungal pathogen causing infectious conditions predominantly
in the elderly and immunocompromised hosts. Although Candida resides as a member
of the oral indigenous microbiota in symbiosis, some circumstances may cause
microbial imbalance leading to dysbiosis and resultant oral candidiasis. Therefore, oral
microbial symbiosis that suppresses the overgrowth of Candida is important for a
healthy oral ecosystem. In this regard, probiotics, prebiotics, and synbiotics can be
considered a potential therapeutic and preventive strategy against oral candidiasis.
Prebiotics have a direct effect on microbial growth as they stimulate the growth of
beneficial bacteria and suppress the growth of pathogens. Probiotics render a local
protective effect against pathogens and a systemic indirect effect on immunological
amelioration. Synbiotics are fusion products of prebiotics and probiotics. This mini
review discusses the potential use and associated limitations of probiotics, prebiotics,
and synbiotics for the prevention and treatment of oral candidiasis. We will also introduce
biogenics, a recent concept derived from the work on probiotics. Biogenics advocates
the use of beneficial bioactive substances produced by probiotic bacteria, whose
activities are independent from the viability of probiotic bacteria in human bodies.
Keywords: probiotics, prebiotics, synbiotics, biogenics, oral candidiasis, lactobacilli
INTRODUCTION
The indigenous microbiota on the surfaces of the skin and mucous membranes plays a role
in preventing the invasion of foreign pathogenic microorganisms. The oral cavity possesses a
diverse set of indigenous microbiota that perpetually interacts with the host mucosal surfaces. The
oral microbiota predominantly comprises bacteria and a small proportion of fungi. Candida is
the major fungus residing even in the healthy human oral cavity (Sardi et al., 2013). However,
depending on circumstances, Candida can transform into a pathogen causing oral infections.
Hence, when there is a collapse in the healthy microbial balance, i.e., dysbiosis, Candida can
proliferate and cause a typical opportunistic infection. Oral candidiasis has been frequently
observed in the elderly population due to problems associated with quality and the production
of saliva, as well as decreased cell-mediated immunity (Scully et al., 1994). Systemic Candida
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infections such as Candida pneumonia and candidemia due
to intravascular indwelling catheters have also been observed
in elderly populations (Eggimann et al., 2003). Recurrent oral
candidiasis occurs frequently in HIV-positive and AIDS patients
(Scully et al., 1994). The administration of antifungal drugs
is generally the ﬁrst-line therapy of candidiasis. However, the
emergence of drug-resistant strains and frequent recurrence
of the disease in aﬀected individuals are increasing challenges
in antifungal therapy (Pfaller and Diekema, 2007). This has
prompted the need for an alternative therapeutic and prevention
strategy. In this mini review, we will succinctly discuss the
potential use of probiotics, prebiotics, and synbiotics as an
alternative antifungal therapy. In addition, a new concept of
biogenics will be introduced. Biogenics is a strategy to overcome
the potential disadvantage of synbiotics, including diﬃculties in
the colonization process of non-native probiotic bacteria. It also
provides an additional advantage to produce functional foods
with bioactive metabolites.
PROBIOTICS
The Definition and History
The term “probiotics,” in contrast to antibiotics, was proposed
by Lilly and Stillwell (1965), from the original ecological
term, “probiosis” used by Kollath (1953), meaning a symbiotic
relationship between organisms. Fuller (1989) deﬁned a probiotic
as “A livemicrobial feed supplement which beneﬁcially aﬀects the
host animal by improving its intestinal microbial balance” (Fuller,
1989). Hence, at that time, probiotics were intended to be used
only for the “intestinal microbiota.” Subsequent studies revealed
general health beneﬁts of probiotics, such as an enhancement
of the human immune system, preventive eﬀects concerning
urinary tract and respiratory tract infections and the allergic
or atopic condition in infants (Gourbeyre et al., 2011). Hence,
probiotics were redeﬁned by Salminen et al. (1998) as “A viable
microbial food supplement which beneﬁcially inﬂuences the
health of the host.” According to the FAO/WHO, probiotics are
deﬁned as “live microorganisms when administered in adequate
amounts confer a health beneﬁt on the host” (FAO/WHO, 2001).
Clinical Trials of Probiotics for Oral
Candida Infections
There has been a gradual increase in the number of studies that
focus on the application of probiotics on oral health (Haukioja,
2010). The majority of these studies have focused on two major
dental diseases, dental caries and periodontitis (Krasse et al.,
2005; Vivekananda et al., 2010; Cagetti et al., 2013). However,
studies on the use of probiotics for oral candidiasis are sparse
(Table 1). Ahola et al. (2002) and Hatakka et al. (2007) conducted
double-blinded, randomized clinical trials using probiotic cheese
on elderly populations with some oral health problems and
carriers of oral Candida compared with a younger cohort (18–
35 years of age). There was an observed trend that the probiotics
could decrease the quantity of Candida. However, the eﬀect was
not signiﬁcant (Ahola et al., 2002) or was small without an
improvement in the mucosal symptom (Hatakka et al., 2007).
On the other hand, studies conducted by Mendonça et al.
(2012), Ishikawa et al. (2015), and Kraft-Bodi et al. (2015)
reported a slight or moderate improvement of oral candidiasis
when patients were treated with probiotics. Dos Santos et al.
(2009) reported a drastic improvement of oral candidiasis upon
probiotic treatment.
In Vivo Animal and In Vitro Studies of
Probiotics for Oral Candida Infections
Several in vivo animal studies have been performed which
have examined the eﬀect of probiotics on oral Candida
infections. However, the results remain controversial. Some
reports suggested a local as well as systemic beneﬁcial eﬀect
of probiotics on candidiasis (Wagner et al., 1997; Elahi et al.,
2005; Matsubara et al., 2012), while others have not observed a
positive eﬀect (Zavisic et al., 2012). These diverse observations
may result from diﬀerences in the administration technique
employed. However, Kojima et al. (2015) demonstrated that the
key factor for the eﬀectiveness of probiotics may be the selection
of an appropriate strain that works against Candida.A diverse set
of Lactobacilli species has been used for the previous probiotic
studies. The genome size of the Lactobacillus genus ranges from
1.23–4.91 Mb and the GC content spans 31.9–57.0% among
diﬀerent species (Cauﬁeld et al., 2015). In addition, the properties
of strains within the same species of Lactobacillus have been
shown to vary (Koll et al., 2008; Tiihonen et al., 2010). Some of
these studies have selected probiotic (Lactobacillus) strains that
are known to confer intestinal health beneﬁts and presume a
similar beneﬁcial eﬀect on oral infections or Candida infections.
Therefore, it is important to demonstrate the in vitro activity
of a probiotic strain against Candida and subsequently select an
eﬃcient strain for in vivo and clinical studies. Such studies are few
and shown in Table 1.
Anti-Candida Products of Probiotics for
Oral Candidiasis
Probiotic lactobacilli co-aggregate with Candida and produce
antimicrobial substances that have a direct growth inhibitory
eﬀect on Candida. Some of these substances produced include
organic acids (e.g., lactic acid and acetic acid), hydrogen peroxide
(H2O2), bacteriocins, and uncharacterized low molecular weight
substances with antifungal properties. Lactobacilli universally
produce lactic acid that inhibits the metabolic activity of Candida
sp. (Köhler et al., 2012), which has a weak antifungal activity
(Zalán et al., 2010). It appears that lactobacilli do not produce
eﬀective concentrations of H2O2 against fungi (Shokryazdan
et al., 2014), unlike other bacteria (Piard and Desmazeaud, 1991).
Lactic acid bacteria produce bacteriocins, proteinaceous
antimicrobial substances with molecular weights of several
thousand daltons or more. Bacteriocins can be divided into
ﬁve classes according to their primary structure, molecular
composition and properties (Chen and Hoover, 2003; Pascual
et al., 2008). Bacteriocin L23 produced by Lactobacillus
fermentum L23 (Pascual et al., 2008), plantaricin produced
by L. plantarum (Sharma and Srivastava, 2014), and pentocin
TV35b produced by L. pentosus (Okkers et al., 1999) appear
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TABLE 1 | Summary of studies that examined the antifungal activity of probiotics against Candida albicans.
Reference Test strains Test design/Feature tested Results
Clinical studies
Ahola et al. (2002) L. rhamnosus GG/LS Intervention with cheese,
Double-blinded placebo RCT
Reduction in the risk of a high level of
Candida
Hatakka et al. (2007) L. lactis,
L. helveticus,
L. rhamnosus GG,
P. freudenreichii
Intervention of an elderly group with cheese for
16 weeks, Double-blinded randomized placebo trial
(tested group, n = 136, control group, n = 140)
10% reduction of the high Candida
count rate in the tested group (after
16-weeks intervention)
Dos Santos et al. (2009) L. casei.
B. breve
No control group, 26 individuals
Intervention with a commercial probiotic drink for
20 days
Reduction of the Candida carrying rate,
reduction of the sIgA level
Mendonça et al. (2012) L. casei,
B. breve
No control group,
42 individuals over 65 years of age
Intervention with a commercial probiotic drink for
30 days
Decrement of Candida prevalence,
increment of sIgA level
Sutula et al. (2013) L. casei No control group, 22 healthy individuals
approximately 32 years of age
Intervention with a commercial probiotic drink for
4 weeks
No reduction of the Candida CFU,
reduction of the halitosis score, did not
detect L. casei after tests
Ishikawa et al. (2015) L. rhamnosus, L. acidophilus,
B. bifidum
Double-blinded randomized trial (tested group,
n = 30, control group, n = 29)
Intervention with trial probiotic products for 5 weeks
Reduction of the Candida carrying rate
in the tested group
Kraft-Bodi et al. (2015) L. reuteri Double-blinded placebo RCT, elderly individuals living
in a nursing home (tested group, n = 84, control
group, n = 90)
Intervention with probiotic lozenges
Improved the Candida score
Animal studies
Wagner et al. (1997) L. acidophilus,
L. reuteri,
L. casei,
B. animalis
Oral candidiasis model in immunodeficient
bg/bg-nu/nu mice
Estimated by the CFU and pathological examinations
Increased the life expectancy in the
tested group
Elahi et al. (2005) L. acidophilus,
L. fermentum
Candida infection model using male DBA/2 mice
(H-2d), 6–8 weeks of age
Oral administration of probiotics
Reduction in the duration of Candida
colonization in the tested group
Matsubara et al. (2012) L. acidophilus,
L. rhamnosus
DBA/2 murine oral Candida infection model. Control
group was treated with nystatin, tested group was
treated with probiotics
Reduction of the Candida level in the
tested group compared with the control
group
Zavisic et al. (2012) L. plantarum,
L. casei
Wister rats and NMRI Ham laboratory mice Did not show an inhibition in C. albicans
growth
Ishijima (2012) S. salivarius ICR mice, oral candidiasis model Probiotics were not fungicidal, but
inhibited Candida adhesion
In vitro test
Chung et al. (1989) L. reuteri MIC assay using partial purified reuterin Reuterin, an anti- microbial substance
with broad spectrum effects, led to the
reduction of C. albicans growth
Koll et al. (2008) L. plantarum,
L. paracasei,
L. salivarius,
L. rhamnosus
Antimicrobial activity was detected using the
antagonism method
Did not show an inhibition in C. albicans
growth
Köhler et al. (2012) L. rhamnosus,
L. reuteri
Antimicrobial activity was detected using an overlay
plate or co-culture assay.
The genome-wide transcriptional profile of C. albicans
was assayed with a cDNA microarray
C. albicans was antisepticized by
inhibition of the metabolic activity under
a low pH
Hasslof et al. (2010) L. plantarum,
L. rhamnosus GG,
L. paracasei,
L. reuteri,
L. acidophilus
Agar overlay interference tests Candida growth was reduced, however,
the effect was generally weaker than for
mutans streptococci
Jiang et al. (2014) L. rhamnosus GG, L. casei,
L. reuteri,
L. brevis,
L. bulgaricus
Estimated the inhibition effect by pH conditions and
the combination of saccharides using EIR
Inhibition capacity differed in the
probiotic strains, L. rhamnosus showed
the strongest inhibition effects against
C. albicans
(Continued)
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TABLE 1 | Continued
Reference Test strains Test design/Feature tested Results
Shokryazdan et al. (2014) L. acidophilus,
L. buchneri,
L. casei,
L. fermentum
Co-culture test with 12 pathogenic microorganisms The active substance was organic acid
Kheradmand et al. (2014) L. johnsonii,
L.plantarum
After selenium treatment, the antimicrobial effects
improved
The active substances were
exometabolities or novel anti-Candida
compounds
Kojima et al. (2015) L. fermentum,
L. plantarum,
L. paracasei
per 12 species (40 strains)
Co-culture and growth inhibition assays of C. albicans
with Lactobacilli culture supernatant or saccharides
Three saccharides and five strains
became candidates for pre- and
probiotics, respectively
to be eﬀective against the yeast form of Candida. Bacteriocins
eﬀective for hyphal forms of Candida have not yet been identiﬁed
(Calderone and Fonzi, 2001; Douglas, 2003). Low molecular
substances of lactobacilli, such as reuterin (Talarico et al., 1988),
reutericyclin (Ganzle, 2000), and dyacetyl (Jay, 1982), have also
been shown to be eﬀective against the yeast forms of Candida
(Chung et al., 1989).
PREBIOTICS
The term “prebiotics” was deﬁned by Gibson and Roberfroid
(1995) as “a non-digestible food ingredient that beneﬁcially
aﬀects the host by selectively stimulating the growth and/or
activity of one or a limited number of bacteria in the colon, and
thus improves host health.” Studies of oral prebiotics are limited.
Sugars and dietary ﬁber have been considered to be prebiotics
for intestinal lactic acid bacteria (Gibson and Roberfroid, 1995).
However, this is not the case for the oral environment, as the
presence of sugars increases the risk of dental caries. The mutans
group of streptococci metabolizes cariogenic sugars, such as
glucose and sucrose, and produces organic acid and insoluble
glucan factors that contribute to dental caries. On the other hand,
sugar alcohols such as xylitol suppress the growth of Streptococcus
mutans. Xylitol, a reduced derivative of xylose, converts to
xylitol-5-phosphate inside S. mutans cells and inhibits glycolysis
(Miyasawa-Hori et al., 2006). Similarly, arabinose, a member
of the same aldopentose group as xylose, is not assimilated by
S. mutans (Coykendall, 1977) and likely has a similar eﬀect
as xylitol. We recently demonstrated that xylitol, xylose, and
arabinose inhibited the growth of S. mutans, but were utilized for
the growth of most of the lactobacilli strains we tested (Kojima
et al., 2015). Although xylitol is generally not assimilated by
lactobacilli, a recent report showed that 36% of lactobacilli strains
isolated from human oral cavities were able to metabolize xylitol
(Almstahl et al., 2013). Meanwhile, our previous data on Candida
albicansATCC18804 showed decreased growth in the presence of
three saccharides (xylitol, xylose, and arabinose) compared with
glucose (Kojima et al., 2015). There are conﬂicting reports on
the ability of C. albicans to assimilate xylitol and aldopentose.
Mäkinen et al. (1975) andMaleszka and Schneider (1982) showed
that C. albicans is not capable of proper growth in the presence of
xylitol. Uittamo et al. (2011) suggested that xylitol metabolism
of Candida might compete for the nicotinamide adenine
dinucleotide (NADH) coenzyme, leading to the downregulation
of alcohol dehydrogenase (ADH). Clinical trials of Turku sugar
studies III and VIII showed signiﬁcantly decreased colony counts
and detection frequency of oral Candida in the xylitol intake
group [Larmas et al. (1974, 1976)]. On the other hand, yeast is
known to possess a pentose assimilation pathway that produces
ethanol from arabinose and xylose by an enzymatic reaction
(Chiang and Knight, 1960; Ônishi and Suzuki, 1966). Even if
Candida is capable of slowly assimilating those three candidate
sugars, the phenomenon of slower growth compared to that of
probiotic bacteria may have a competitive inhibition on Candida.
The presence of xylitol inhibits the adhesion of Candida to
mucosal surfaces (Pizzo et al., 2000; Abu-Elteen, 2005). In an
experimental murine model of gastrointestinal candidiasis, the
colonization and invasion of C. albicans was signiﬁcantly reduced
in the group supplemented with xylitol compared to the group
supplemented with glucose (Vargas et al., 1993).
SYNBIOTICS
The Noteworthy Features of Synbiotics
Associated with the Oral Application
Gibson and Roberfroid (1995) proposed the use of probiotics and
prebiotics fusion products or “synbiotics” for the intestinal tract
microbiota (Panigrahi et al., 2008). However, the use of synbiotics
for the oral microbiota has not been well studied (Kojima et al.,
2015). It is important to understand the limitations associated
with the oral application of synbiotics. Probiotic bacteria are not
able to easily colonize adult oral cavities (Lazarevic et al., 2010;
Tiihonen et al., 2010). Therefore, it appears that synbiotics are
more eﬀective for oral applications than probiotics alone. One
must, however, consider the risk of dental caries while applying
lactic acid bacteria in the oral cavity. Lactobacilli have long
been considered to be one of the cariogenic bacteria present in
dental plaque (Glass, 1952). Currently, there are two concepts
on the association of lactobacilli with dental caries. Lactobacilli
comprise a very small proportion of normal oral microbiota and
are primarily present on the tongue dorsum, rather than in dental
plaque (vanHoute et al., 1972). However, they are hardly detected
in the oral cavity of caries-free individuals (Yang et al., 2010).
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The lactobacilli count in the saliva is an indicator of the dental
caries activity as lactobacilli penetrate porous tooth surfaces in
early caries lesions or adhere to type I collagen exposed in the
carious portion of the tooth (Cauﬁeld et al., 2015). As the salivary
lactobacilli count correlates with the amount and frequency
of carbohydrate (sugar) intake (Jay, 1947; Becks, 1950), the
presence of lactobacilli is a reliable indicator for the dental caries
activity (Crossner, 1981). Therefore, if one can maintain good
oral hygiene, oral probiotic therapy with lactobacilli alone may
not contribute to the development of dental caries. In addition,
if appropriate prebiotics are administered simultaneously, then
synbiotic therapy may suppress the development of oral
candidiasis.
The Different Immune Responses
Associated with Synbiotics in the
Intestinal Tracts or Oral Cavities
The important considerations for synbiotic therapy of the
intestine and oral cavity are the host immune component and
reactions. While activation of a substantial host immune response
can be expected in the intestine, a similar phenomenon is not
expected in the oral cavity as it is not an organ of mucosa-
associated lymphoid tissues (MALT). In the intestine, probiotic
bacteria are incorporated into M cells in Peyer’s patches (PP),
which is a major component of gut-associated lymphoid tissues
(GALT), and digested to form active antigens. Macrophages
and dendritic cells in PP phagocytize probiotic bacteria and are
activated to produce several cytokines, which stimulate T-cell
and B-cell functions (Matsuzaki et al., 2007). Moreover, daily
supplementation of lactobacilli as part of a normal diet increased
the number and activity of natural killer cells in healthy elderly
individuals (Tiihonen et al., 2010). Thus, synbiotics in the
intestinal tract can be expected to activate both innate immunity
and acquired immunity of cell-mediated and humoral immunity.
Conversely, the oral cavity it is not an immune organ and
phenomenon such as direct antigen presentation to adaptive
immune cells does not occur. Nevertheless, some probiotic
clinical trials and animal studies using oral candidiasis models
have reported an increase of sIgA against Candida, leading to the
suppression of Candida in the oral cavity (Wagner et al., 1997;
Elahi et al., 2005; Mendonça et al., 2012). It is well known that
secretion of sIgA at the salivary gland is through diﬀerentiated
plasma cells from B cells stimulated at MALT. According to
the results of clinical and animal studies described above, oral
synbiotics appear to transition into intestinal synbiotics, as the
oral cavity is connected to the intestine. Children who were oral
lactobacilli carriers were found to have similar lactobacilli in their
feces (Cauﬁeld et al., 2015). Hence, it appears that the intestinal
colonization of lactobacilli is transmitted though the oral cavity,
which may provide simultaneous synbiotic activity at the oral
cavity and the intestine.
BIOGENICS
Previous studies have highlighted the limitation of colonization
and ﬁxation of non-nature probiotic bacteria in the intestinal
tracts of human bodies (Haenel, 1960; Mitsuoka and Kaneuchi,
1977). This scenario is also relevant for the probiotic application
in oral cavities, particularly when considering the associated
risk of oral probiotics and dental caries. In order to address
foregoing concerns, the concept of “biogenics” has been
suggested as a solution (Mitsuoka, 2000). Biogenics is deﬁned as
FIGURE 1 | Anti-Candida effects with synchronized prebiotics, probiotics, biogenics, and immunological resistance.
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“food ingredients which beneﬁcially aﬀect the host by directly
immunostimulating or suppressing mutagenesis, tumorigenesis,
peroxidation, hypercholesterolemia, or intestinal putrefaction”
(Mitsuoka, 2000). Hence, previous studies have suggested the
administration of non-viable probiotic bacteria to obtain some
“probiotic” eﬀects. It was reported that the consumption of
pasteurized fermented milk elongated the lifespan of mice (Arai
et al., 1980; Takano et al., 1985). A signiﬁcant reduction of the
Ehrlich ascites tumor growth in mice was also reported (Takano
et al., 1985). In addition, it was shown that heat-inactivated
Enterococcus faecalis (Terada et al., 2004) or L. gasseri (Sawada
et al., 2016) retained a beneﬁcial regulatory function in the
gut. Moreover, Nakamura et al. (1995) identiﬁed an angiotensin
I-converting enzyme (ACE) inhibitor in a Japanese sterilized
milk beverage fermented by L. helveticus and Saccharomyces
cerevisiae.The active substance was lactotripeptides metabolically
generated in the fermentation pathway. Follow-up studies were
able to determine the bioactive metabolites of probiotic bacteria
in addition to the antimicrobial substances, such as bacteriocin
(Ross et al., 2010; O’Shea et al., 2012), and other beneﬁcial
active substances, such as conjugated linoleic acid (CLA; Hayes
et al., 2006; Ross et al., 2010; O’Shea et al., 2012), protein or
peptides (Möller et al., 2008; Bogsan et al., 2013), and polyphenols
(Dharmaraj, 2010; Monagas et al., 2010). Taking all these
observations into account, the new concept, biogenics, which
makes use of the bioactive metabolites as foods or medicine,
was recently advocated (Mitsuoka, 2000, 2014). The biogenics
eﬀect is independent of the colonization and viability of probiotic
bacteria. Hence, biogenics is the direct delivery of an isolated and
puriﬁed active ingredient of probiotics to the local environment.
This strategy may also be used as an antifungal therapy. It may
be possible to purify the active ingredients of probiotic bacteria
that demonstrate antifungal activity for use in the biogenics
process. However, this idea requires further study before clinical
use.
CONCLUSION
Taking the abovementioned studies into consideration, it is
conceivable that an innovative combination of prebiotics,
probiotics, synbiotics, and biogenics instrumental in devising a
successful, novel antifungal regime in the future (Figure 1). More
comprehensive investigations on the mechanism of synbiotics
and biogenics are needed for this purpose. Hence, more studies
are warranted to examine the bioactive metabolites of probiotic
bacteria that induce favorable immunological outcomes and
suppress Candida infection in the human oral cavity.
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